Lenzing Aktiengesellschaft
Austria · AT0000644505 · reports in EUR · Europe
The answers
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Is it growing?Fair
- Revenue −2.3% in the year to Dec 31, 2025, on the year before.
- Is it a good business?To watch
- It earned −14% on its shareholders' equity in the year to Dec 31, 2025.
- Is it safe?Fair
- Equity is 28% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in EUR.
revenue
operating margin
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | €2.6B | €2.5B | €2.7B | €2.6B |
| Operating profit | €16M | −€476M | €89M | €18M |
| Earnings per share | −€20.02 | −€2.75 | n/a | n/a |
| Cash from operations | −€43M | €160M | €395M | €420M |
| Cash | €447M | €726M | €442M | €675M |
| Total assets | €5.5B | €5.2B | €5.0B | €4.6B |
| Equity | €2.0B | €1.7B | €1.7B | €1.3B |
What they do
In the company's own words, from the annual report.
Das Kerngeschäft der Lenzing Gruppe liegt in der Erzeugung und Vermarktung von regenerierten Cellulosefasern. Der zur Erzeugung notwendige Zellstoff wird zu einem gewichtigen Teil in eigenen Zellstoffwerken hergestellt bzw. teilweise zugekauft.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.